Dextrothyroxine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Dextrothyroxine
Dextrothyroxine skeletal.svg
Clinical data
Trade names Choloxin
AHFS/Drugs.com Multum Consumer Information
Pregnancy
category
  • US: B (No risk in non-human studies)
ATC code
Legal status
Legal status
  • Discontinued
Identifiers
Synonyms D-3,5,3',5'-tetraiodothyronine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEBI
ChEMBL
ECHA InfoCard 100.000.094
Chemical and physical data
Formula C15H11I4NO4
Molar mass 776.87 g/mol
3D model (JSmol)

Dextrothyroxine (trade name Choloxin) saw research as a cholesterol-lowering drug[1][2] but was pulled due to cardiac side-effects. It also increases hepatic lipase which in turn improves utilization of triglycerides, improving apolipoprotein E cholesterol particles.[citation needed]

See also[edit]

References[edit]

  1. ^ Bantle, J. P.; Hunninghake, D. B.; Frantz, I. D.; Kuba, K.; Mariash, C. N.; Oppenheimer, J. H. (1984). "Comparison of effectiveness of thyrotropin-suppressive doses of D- and L-thyroxine in treatment of hypercholesterolemia". The American Journal of Medicine. 77 (3): 475–481. PMID 6475988. doi:10.1016/0002-9343(84)90107-4. 
  2. ^ Bommer, C.; Werle, E.; Walter-Sack, I.; Keller, C.; Gehlen, F.; Wanner, C.; Nauck, M.; März, W.; Wieland, H.; Bommer, J. (1998). "D-thyroxine reduces lipoprotein(a) serum concentration in dialysis patients". Journal of the American Society of Nephrology : JASN. 9 (1): 90–96. PMID 9440092.